Streetbeat News

Stock Prices

HOOD

Deep-pocketed investors are showing a significant bearish sentiment towards Robinhood Markets (NASDAQ:HOOD), as revealed by Benzinga's tracking of public options records. A notable volume of options activity was observed, with 68% of investors leaning bearish. The price band focused on by major market movers is between $8.0 and $37.0. Currently, HOOD's stock is down by -1.14%, trading at $19.9, with an anticipated earnings release in 37 days. Analysts have mixed opinions, with an average target price of $22.6.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:31 pm

AEON

EIGR

SBFM

XLO

In Monday's intraday session, health care stocks saw significant movements. Sunshine Biopharma, Xilio Therapeutics, Akanda, Mesoblast, Brainstorm Cell, and Adagene were among the gainers with notable percentage increases in their stock prices. On the downside, Eiger BioPharmaceuticals, Disc Medicine, AEON Biopharma, Biora Therapeutics, Sharecare, and ENDRA Life Sciences experienced substantial declines. The movements were attributed to various factors including quarterly earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:31 pm

NVVE

SMXT

SOL

VSTE

In Monday's intraday session, several industrials stocks experienced significant movements. Vast Renewables (VSTE) saw a notable increase of 171.5%, while Nuvve Holding (NVVE) faced a sharp decline of 28.2%. Other stocks such as Emeren Group (SOL) and SolarMax Technology (SMXT) also saw considerable gains, attributed to recent earnings reports. Conversely, companies like Laser Photonics (LASE) and Expion360 (XPON) experienced declines following their earnings announcements.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:31 pm

CXAI

INLX

MMAT

ONDS

In Monday's intraday session, several information technology stocks showed significant movement. CXApp, Meta Materials, and Ondas Holdings were among the top gainers, with CXApp leading at a 156.4% increase. On the losing end, Intellinetics, Sobr Safe, and Strong Global saw notable declines, with Intellinetics dropping by 23.2%. These movements reflect the dynamic nature of the tech stock market, influenced by factors such as quarterly earnings reports.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:30 pm

APLT

The FDA has extended the review period for Applied Therapeutics Inc's New Drug Application for govorestat, a treatment for Classic Galactosemia, by three months, setting a new PDUFA target action date of November 28, 2024. This extension is due to the FDA requiring additional time to review supplemental analyses provided by Applied Therapeutics. The company announced in February 2024 that the FDA granted Priority Review to the NDA, and if approved, govorestat would be Applied Therapeutics' first commercial product. Additionally, the company has submitted a Marketing Authorization Application for govorestat to the EMA, expecting a decision in Q4 2024. Applied Therapeutics reported having $153.5 million in cash as of March 1, 2024, with a cash runway into the first half of 2026. The company's shares are down 6.99% at $6.325.

Portfolio Pulse from Vandana Singh

April 01, 2024 | 4:30 pm

IMO

Imperial Oil (AMEX:IMO) has delivered an average annual return of 20.55% over the past 5 years, outperforming the market by 7.97%. A $100 investment in IMO 5 years ago would now be worth $257.29. The company currently has a market capitalization of $37.28 billion.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:30 pm

JBL

Over the past 5 years, Jabil (NYSE:JBL) has outperformed the market with an annualized return of 23.33%, averaging 35.9% annually. A $1000 investment in JBL 5 years ago would now be worth $4,676.24. Jabil's market capitalization stands at $17.24 billion.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 4:30 pm

Home Depot Inc (NYSE:HD) shares fell after announcing the acquisition of SRS Distribution for $18.25 billion. Analysts from Wedbush and Telsey Advisory Group predict the acquisition will strengthen Home Depot's market positioning and drive earnings growth. Wedbush raised its price target from $380 to $410, citing the deal's potential to increase Home Depot's total addressable market by $50 billion. Telsey Advisory Group raised its price target from $335 to $360, noting the acquisition's accretive impact on non-GAAP earnings, despite being dilutive on a GAAP basis due to amortization expense.

Portfolio Pulse from Priya Nigam

April 01, 2024 | 4:29 pm

ASML

ASML shares are trading higher amid overall strength in semiconductor stocks.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 4:28 pm

MRVL

Marvell Technology shares are trading higher due to overall strength in the semiconductor sector.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 4:27 pm